Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT02235077

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02235077
Other papers using this trial's data
  • Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial JAMA cardiology, 2017-09-01 DOI, PubMed 28700781, PMC5675712 Not in the PMC Open Access subset.
  • Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial The Canadian journal of cardiology, 2019-09 DOI, PubMed 31230825, PMC6685766 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02235077. Randomized; triple masking; primary purpose treatment. Start 2014-12-30 (actual); primary completion 2016-04-12 (actual). Results posted on 2017-05-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
Acronym
ATHENA-HF
Condition
Heart Failure
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
Duke University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct02235077
Content hash
f861ba58e7a947ae43eb41ea4aee91737e2d4f050ad1e076d70d7a36b58f9382